EFM
ABUS icon

E Fund Management’s Arbutus Biopharma ABUS Stock Holding History

E Fund Management’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.1K Sell
14,406
-1,037
-7% -$4.55K ﹤0.01% 481
2026
Q1 		$69.5K Buy
+15,443
New +$67.5K ﹤0.01% 481
2025
Q1 		– Sell
-10,385
Closed -$34K – 399
2024
Q4 		$34K Buy
+10,385
New +$38.2K ﹤0.01% 390

Other funds holding ABUS

TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
WCM
Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

E Fund Management's ABUS Position: Q2 2026 in Review

E Fund Management reduced its Arbutus Biopharma (ABUS) stake by 6.7% in Q2 2026, selling an estimated $4.55K and leaving 14,406 shares worth $69.1K. The position accounts for ﹤0.01% of the portfolio, ranked #481.

E Fund Management first reported a position in ABUS in Q4 2024 and has held it in 3 quarters since. The position peaked at $69.5K in Q1 2026. 177 funds tracked by Wall St. Rank hold ABUS as of Q2 2026.

  • E Fund Management held 14,406 shares of Arbutus Biopharma worth $69.1K as of Q2 2026.
  • E Fund Management sold 1,037 Arbutus Biopharma shares in Q2 2026, an estimated $4.55K.
  • Arbutus Biopharma made up ﹤0.01% of E Fund Management's portfolio in Q2 2026, its #481 holding.
  • E Fund Management first reported a position in Arbutus Biopharma in Q4 2024 and has held it in 3 quarters since.
  • E Fund Management's Arbutus Biopharma position peaked at $69.5K in Q1 2026.
  • 177 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2026.

Based on E Fund Management's 13F filing for Q2 2026, filed 11 Aug 2026.